Notebook

Contents Trial veteran Resistance in rivers I contain multitudes Chlamydia in heart disease Tomatoes vs. armyworms Look, Ma, no paws Peroxide damage Philip Brunell receives the first injection at NIH of the experimental shingles vaccine from nurse Patricia Hohman. TRIAL VETERAN When Philip Brunell received the first shingles vaccination in a Phase III trial June 17, it was not exactly a shot in the dark. The senior attending physician at the National Institutes of Health clinical center estim

Written byPaul Smaglik
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Contents Trial veteran Resistance in rivers I contain multitudes Chlamydia in heart disease Tomatoes vs. armyworms Look, Ma, no paws Peroxide damage Philip Brunell receives the first injection at NIH of the experimental shingles vaccine from nurse Patricia Hohman. TRIAL VETERAN When Philip Brunell received the first shingles vaccination in a Phase III trial June 17, it was not exactly a shot in the dark. The senior attending physician at the National Institutes of Health clinical center estimates he's been injected in the name of science 20-30 times. "Whenever we've had a vaccine trial and I've been eligible, I've taken the first dose." The National Institute of Allergy and Infectious Diseases trial tests a more potent version of the vaccine used to immunize children against the chicken pox to cause an immune response against varicella-zoster virus (VZV). VZV causes both shingles and chicken pox. The virus remains dormant in nerve ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies